Targeting Shared Mechanisms in Atherosclerosis and Alzheimer's Disease

Devesh B Chaudhari1, Kalyani Barve1

  • 1Department of Pharmacology, Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-be-University, Maharashtra, Vile Parle (W), Mumbai, India.

Insights

Atherosclerosis and Alzheimer's Disease share inflammatory and metabolic pathways. Targeting these common mechanisms, like the NLRP3 inflammasome, offers potential dual therapeutic benefits for both conditions.

Area of Science:

  • Neuroscience
  • Cardiovascular Science
  • Immunology

Background:

  • Atherosclerosis and Alzheimer's Disease share pathological hallmarks including inflammation, oxidative stress, and lipid dysregulation.
  • Vascular dysfunction in atherosclerosis exacerbates amyloid-beta (Aβ) plaque accumulation in Alzheimer's Disease by impairing cerebral blood flow and Aβ clearance.

Purpose of the Study:

  • To review shared pathophysiological pathways between atherosclerosis and Alzheimer's Disease.
  • To highlight the potential of targeting common molecular mechanisms for dual therapeutic strategies.

Main Methods:

  • Review of preclinical studies and emerging therapeutic agents.
  • Examination of key molecular players: NLRP3 inflammasome, Receptor for Advanced Glycation End Products, and apolipoprotein E4.
  • Analysis of microRNA-based therapies and lipid metabolism modulators.

Main Results:

  • NLRP3 inflammasome inhibitors (e.g., MCC950) and microRNA therapies (e.g., miR-146a) show promise in preclinical models.
  • Lipid metabolism modulators (e.g., T0901317, Anacetrapib) offer potential dual cardiovascular and neurological benefits.
  • Challenges include Blood-Brain Barrier permeability, genetic variability, and limited clinical data.

Conclusions:

  • Targeting shared pathways like inflammation and lipid metabolism presents a promising therapeutic avenue for both atherosclerosis and Alzheimer's Disease.
  • Multimodal therapies combining anti-inflammatory, lipid-regulatory, and antioxidant strategies are recommended.
  • Personalized medicine approaches leveraging advanced molecular and imaging techniques are crucial for future treatment development.

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...